46 results on '"Bowcock, Stella"'
Search Results
2. Determinants of durable humoral and T cell immunity in myeloma patients following COVID‐19 vaccination
3. Levofloxacin prophylaxis in patients with newly diagnosed myeloma (TEAMM): a multicentre, double-blind, placebo-controlled, randomised, phase 3 trial
4. Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in adults with haematological malignancies: a phase 3, randomised, clinical trial and post-hoc efficacy analysis
5. Unplanned admissions for patients with myeloma in the UK: Low frequency but high costs
6. Determinants of durable humoral and T cell immunity in myeloma patients following COVID‐19 vaccination.
7. P-378 Longitudinal antibody and T-cell kinetics over four doses of COVID-19 vaccination and predictors of poor response in patients with multiple myeloma
8. Anti-bacterial antibodies in multiple myeloma patients at disease presentation, in response to therapy and in remission: implications for patient management
9. Presenting Symptoms in Newly Diagnosed Myeloma, Relation to Organ Damage, and Implications for Symptom-Directed Screening: A Secondary Analysis from the Tackling Early Morbidity and Mortality in Myeloma (TEAMM) Trial
10. Patient-reported symptoms and diagnostic journey in Multiple Myeloma.
11. High numbers of COVID-19 patients transit through non-COVID wards, and associated healthcare workers have high infection rates: An observational cross-sectional study
12. Frailty-adjusted therapy in Transplant Non-Eligible patients with newly diagnosed Multiple Myeloma (FiTNEss (UK-MRA Myeloma XIV Trial)): a study protocol for a randomised phase III trial
13. Guidelines for screening and management of late and long‐term consequences of myeloma and its treatment
14. Cryptococcosis in late stage multiple myeloma: consider it
15. Immune response to COVID‐19 vaccination is attenuated by poor disease control and antimyeloma therapy with vaccine driven divergent T‐cell response
16. Fitness, a UK Myeloma Research Alliance (UK-MRA) Frailty-Adjusted Therapy Study, Supports the Feasibility of Recruiting Frail Newly Diagnosed Myeloma Patients to Large Clinical Trials
17. Immune response to COVID-19 vaccination is attenuated by poor disease control and antimyeloma therapy with vaccine driven divergent T cell response
18. COVID symptoms, testing, shielding impact on patient‐reported outcomes and early vaccine responses in individuals with multiple myeloma
19. Health-Related Quality of Life (HRQoL) in Fit, Unfit and Frail Patients Enrolled in Fitness (UK-MRA Myeloma XIV): A Cross Sectional Study
20. Real-World Mobilization, Harvest, and Transplant Outcomes in Newly Diagnosed Multiple Myeloma Patients Receiving D-VTd: A UK Centre Experience
21. Time to redefine Myeloma
22. Use of patient diaries in conjunction with standard reporting methods: duplication of data or a valuable resource?
23. Stratifying risk of infection and response to therapy in patients with myeloma: a prognostic study
24. Survival trends in elderly myeloma patients
25. Levofloxacin prophylaxis in patients with myeloma – Authors' reply
26. Frailty-Adjusted Therapy in Transplant Non-Eligible Patients with Newly Diagnosed Multiple Myeloma (FiTNEss): A UK Myeloma Research Alliance Study, Myeloma XIV
27. Prophylactic levofloxacin to prevent infections in newly diagnosed symptomatic myeloma: the TEAMM RCT
28. COVID symptoms, testing, shielding impact on patient‐reported outcomes and early vaccine responses in individuals with multiple myeloma.
29. Comparing clinical trial data against a real world dataset – progression-free survival on Len/Dex and Bor/Dex following 1-3 prior lines of treatment
30. Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in adults with haematological malignancies: a phase 3, randomised, clinical trial and post-hoc efficacy analysis
31. Excluding myeloma diagnosis using revised thresholds for serum free light chain ratios and M-protein levels
32. The combination of an inclusive novel agent treatment strategy, pre‐emptive therapy dose reduction, and prolonged therapy results in good outcomes in elderly myeloma patients
33. Levofloxacin Prophylaxis in Newly Diagnosed Myeloma Patients
34. Elective Vs Non-Elective Hospital Admissions By Patients with Multiple Myeloma in England 2014 - 2018
35. 149. Immunogenicity, Safety, and Post-hoc Efficacy Assessment of the Adjuvanted Recombinant Zoster Vaccine in Adults with Hematologic Malignancies: A Phase 3, Randomized Clinical Trial
36. Diagnostic pathways in multiple myeloma and their relationship to end organ damage: an analysis from the Tackling Early Morbidity and Mortality in Myeloma (TEAMM) trial.
37. Survival trends in elderly myeloma patients.
38. Tackling Early Morbidity and Mortality in Myeloma (TEAMM): Assessing the Benefit of Antibiotic Prophylaxis and Its Effect on Healthcare Associated Infections in 977 Patients
39. Outcome for patients with relapsed/refractory aggressive lymphoma treated with gemcitabine and oxaliplatin with or without rituximab; a retrospective, multicentre study
40. Dynamic Frailty Assessment in Transplant Non-Eligible Newly Diagnosed Myeloma Patients: Initial Data from UK Myeloma Research Alliance (UK-MRA) Myeloma XIV (FiTNEss): A Frailty-Adjusted Therapy Study
41. Diagnostic Pathways of Myeloma Patients Presenting to Hospital Care and Relationship to End Organ Damage: An Analysis from the Teamm (Tackling EArly Morbidity and Mortality in Myeloma) Trial in 977 Patients
42. Assessment of Anti-Bacterial Antibodies in Multiple Myeloma Patients at Disease Presentation and in Response to Therapy: Implication for Patient Management
43. Longitudinal dynamics and clinically available predictors of poor response to COVID-19 vaccination in multiple myeloma.
44. F railty-adjusted therapy i n T ransplant N on- E ligible patient s with newly diagno s ed Multiple Myeloma (FiTNEss (UK-MRA Myeloma XIV Trial)): a study protocol for a randomised phase III trial.
45. Stratifying risk of infection and response to therapy in patients with myeloma: a prognostic study
46. Excluding myeloma diagnosis using revised thresholds for serum free light chain ratios and M-protein levels.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.